Pancreatic neuroendocrine tumors that have spread to other parts of the body represent a complex and challenging form of cancer that requires specialized care and a multidisciplinary approach to treatment.

Understanding the Disease

When pancreatic neuroendocrine tumors spread beyond the pancreas to other organs, they are called metastatic. These tumors develop from the hormone-producing cells in the pancreas, known as islet cells, which normally help regulate important body functions like blood sugar control. Unlike the more common type of pancreatic cancer called adenocarcinoma, these tumors tend to grow more slowly and often have a different outlook for patients.^[1]

The metastatic form means that cancer cells have traveled from the original tumor in the pancreas to distant organs, most commonly the liver. The liver is frequently affected because of its role in filtering blood from the digestive system, which gives cancer cells an opportunity to establish new tumors there. In some cases, the disease can also spread to the spleen, bones, and other distant sites throughout the body.^[3]

These tumors can be classified as either functional or nonfunctional. Functional tumors produce excess amounts of hormones, which creates noticeable symptoms related to that specific hormone. For example, a tumor making too much insulin might cause dangerous drops in blood sugar, while one producing gastrin might lead to severe stomach ulcers. Nonfunctional tumors, which represent the majority of cases, do not produce extra hormones. Because they don’t cause hormone-related symptoms, these tumors are often discovered only after they have already spread and grown large enough to affect nearby organs.^[2]

Epidemiology

Pancreatic neuroendocrine tumors are considered rare diseases, making up only about two percent of all pancreatic tumors. The clinical incidence is reported to be between one and five new cases per 100,000 people each year, with a prevalence of approximately 10 cases per 100,000 population. However, recent data suggests that the number of people being diagnosed with these tumors has been increasing, likely due to improved diagnostic imaging technologies that can detect tumors earlier and more accurately.^[6]

These tumors account for around eight percent of all pancreatic tumors when including both benign and malignant forms. While they can occur at any age, most people diagnosed are between the ages of 50 and 60 years old. The disease is relatively uncommon in children, teenagers, and young adults, though cases can occur in younger individuals as well.^[5][8]

When it comes to metastatic disease specifically, the outlook varies significantly depending on whether the tumors are well-differentiated or poorly differentiated. Well-differentiated tumors, which grow more slowly, are associated with better survival rates. The frequency of malignancy ranges from 50 to 80 percent for most types of pancreatic neuroendocrine tumors, with the notable exception of insulinomas, which are usually benign. Unfortunately, nonfunctional tumors, which make up as many as 90 percent of cases, often already show signs of metastasis at the time of diagnosis because they don’t produce early warning symptoms.^[6]

Causes

The exact cause of pancreatic neuroendocrine tumors remains largely unknown. Researchers have not yet identified what triggers the neuroendocrine cells in the pancreas to begin dividing and multiplying uncontrollably, eventually forming tumors that can spread to other organs. What is understood is that these tumors develop when there are abnormal changes in the cells’ normal growth and division processes.^[7]

Unlike some other forms of cancer, there are no clear environmental triggers or lifestyle factors that have been definitively linked to the development of these tumors. The disease does not appear to be caused by smoking, excessive alcohol consumption, or dietary factors in the way that pancreatic adenocarcinoma might be. This makes prevention particularly challenging, as there are no obvious behaviors or exposures to avoid.^[1]

Risk Factors

While the direct causes of pancreatic neuroendocrine tumors are not well understood, certain inherited genetic conditions significantly increase a person’s risk of developing these tumors. The most important risk factor is having one of several rare hereditary syndromes that involve mutations in specific genes. These genetic conditions are passed down through families and can cause multiple tumors to develop in various organs throughout the body.^[8]

The most common inherited syndrome associated with pancreatic neuroendocrine tumors is Multiple Endocrine Neoplasia Type 1, also known as MEN1 or Wermer Syndrome. This condition causes overactive tumors to form in various endocrine glands, including the pancreas, parathyroid glands, and pituitary gland. When tumors develop as part of MEN1, they may appear in multiple locations within the pancreas and can have a very high potential to become malignant and spread.^[5][8]

For individuals with these hereditary syndromes, regular monitoring and screening can help detect tumors early, potentially before they have spread to other organs. Genetic testing and counseling are important tools for families with a history of these conditions, as they can help identify who might be at increased risk and would benefit from closer medical surveillance.^[1]

Symptoms

The symptoms of metastatic pancreatic neuroendocrine tumors vary widely depending on whether the tumor is functional or nonfunctional, and where in the body the cancer has spread. Many patients experience a long period where they either have no symptoms at all or have vague complaints that are easily attributed to other, less serious conditions. This is particularly true for nonfunctional tumors, which can grow silently for years without causing any hormone-related problems.^[1]

When functional tumors are present, the symptoms relate directly to the type of hormone being overproduced. A tumor producing excessive insulin, called an insulinoma, causes dangerous drops in blood sugar that lead to dizziness, blurred vision, headaches, weakness, and confusion. Patients may experience intense hunger and sweating as their body tries to cope with the low blood sugar levels. A gastrinoma, which produces too much gastrin, creates severe heartburn, stomach ulcers, abdominal pain, and persistent diarrhea as stomach acid production goes into overdrive.^[2]

Nonfunctional tumors typically only cause symptoms once they have grown large enough to affect nearby organs or have spread extensively throughout the body. Common complaints include persistent abdominal pain that may radiate to the back, a feeling of fullness or bloating, unexplained weight loss, and extreme fatigue. Some patients notice yellowing of their skin and the whites of their eyes, a condition called jaundice, which occurs when tumors block bile ducts. Others experience digestive problems like nausea, vomiting, diarrhea, or constipation.^[1]

When the disease has metastasized to the liver, which is very common, the liver may become enlarged and cause abdominal distension. Patients might notice their abdomen appears swollen or feels uncomfortable. If the cancer has spread to bones, as happened in some documented cases, it can cause pain in the affected areas, such as back pain when vertebrae are involved. The combination of advanced disease and liver involvement often leads to a general decline in health, with patients feeling increasingly unwell, losing their appetite, and struggling with persistent digestive symptoms.^[3]

Prevention

Unfortunately, there are no established methods for preventing pancreatic neuroendocrine tumors in the general population. Because the exact causes of these tumors remain unknown and they are not linked to specific lifestyle factors or environmental exposures, there are no clear preventive measures that people can take to reduce their risk. This stands in contrast to some other cancers where avoiding tobacco, maintaining a healthy weight, or limiting alcohol consumption can meaningfully reduce disease risk.^[7]

For individuals who have inherited genetic syndromes like Multiple Endocrine Neoplasia Type 1, prevention focuses on early detection rather than avoiding tumor development altogether. These high-risk individuals benefit from regular screening programs that include blood tests to measure hormone levels and imaging studies to look for tumors before they cause symptoms or spread. Finding tumors when they are still small and confined to the pancreas offers the best chance for successful treatment and potentially curative surgery.^[8]

Genetic counseling plays an important role for families with a history of inherited syndromes associated with these tumors. Understanding who in the family carries genetic mutations that increase risk allows for personalized surveillance plans. Family members who test positive for these mutations can begin monitoring programs early, while those who test negative can be reassured that they do not face the same elevated risk.^[1]

Pathophysiology

The pathophysiology of metastatic pancreatic neuroendocrine tumors involves complex changes in how cells normally function and regulate their growth. These tumors originate from neuroendocrine cells in the pancreas, which are specialized cells that combine characteristics of both nerve cells and hormone-producing endocrine cells. Under normal circumstances, these cells cluster together in small groups called islets of Langerhans, where they produce vital hormones like insulin and glucagon that help regulate blood sugar levels and other metabolic processes.^[2]

When neuroendocrine cells become cancerous, they lose the normal controls that regulate cell division and death. Instead of dividing at appropriate rates and dying when they should, these abnormal cells multiply uncontrollably and fail to undergo normal programmed cell death. Over time, this leads to the formation of tumors within the pancreas. The tumors themselves can vary significantly in their behavior, with some growing very slowly over many years while others are more aggressive.^[1]

The grade and differentiation of these tumors profoundly affect how they behave. Well-differentiated tumors maintain more characteristics of normal neuroendocrine cells and tend to grow more slowly. They are often classified by their Ki67 proliferation index, which measures how rapidly cancer cells are dividing. A lower Ki67 index indicates slower-growing tumors with a more indolent course. Poorly differentiated tumors, in contrast, have lost most of their normal cell characteristics and behave much more aggressively, similar to small-cell lung cancer. These high-grade tumors divide rapidly and are more likely to spread quickly to distant organs.^[3]

The process of metastasis occurs when cancer cells break away from the original tumor in the pancreas and travel through the bloodstream or lymphatic system to establish new tumors in distant organs. The liver is the most common site of metastasis because blood from the pancreas and digestive system flows through the liver for filtering. This anatomical relationship gives pancreatic neuroendocrine tumor cells direct access to liver tissue. Once established in the liver, metastatic tumors can grow to occupy significant portions of the organ, sometimes appearing as thousands of lesions scattered throughout liver tissue.^[6]

In functional tumors, the cancer cells retain their ability to produce hormones, but without the normal regulatory controls. This leads to excessive, uncontrolled hormone production that overwhelms the body’s ability to maintain balance. For instance, insulinomas produce dangerous amounts of insulin that drive blood sugar to perilously low levels, while gastrinomas flood the body with gastrin, causing the stomach to produce excessive acid that damages the digestive tract lining. These hormonal imbalances create many of the clinical symptoms patients experience and can significantly impact their quality of life.^[2]

The biological differences between pancreatic neuroendocrine tumors and the more common pancreatic adenocarcinoma are substantial and explain why their clinical courses differ so dramatically. Neuroendocrine tumors are believed to originate from different cells within the pancreas and have distinct molecular characteristics. They typically grow more slowly and often remain more responsive to treatments even after spreading, allowing many patients to live for years with metastatic disease. This more indolent behavior contrasts sharply with adenocarcinoma, which tends to be aggressive from the outset and has a much worse prognosis once it has spread.^[9]